Clinical Cancer Advances 2005: Major research advances in cancer treatment, prevention, and screening - A report from the American Society of Clinical Oncology

Journal of Clinical Oncology

Volumn 24, Issue 1, 2006, Pages 190-205

  Herbst, Roy S ^a   Bajorin, Dean F ^a   Bleiberg, Harry ^a   Blum, Diane ^a   Hao, Desirée ^a   Johnson, Bruce E ^a   Ozols, Robert F ^a   Demetri, George D ^a   Ganz, Patricia A ^a   Kris, Mark G ^a   Levin, Bernard ^a   Markman, Maurie ^a   Raghavan, Derek ^a   Reaman, Gregory H ^a   Sawaya, Raymond ^a   Schuchter, Lynn M ^a   Sweetenham, John W ^a   Vahdat, Linda T ^a   Vokes, Everett E ^a   Winn, Rodger J ^a   Mayer, Robert J ^a   Bentsen, Todd ^a   more..

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AROMATASE INHIBITOR; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; ESTROGEN; FLUOROURACIL; FOLINIC ACID; IMATINIB; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PACLITAXEL; PLACEBO; SUNITINIB; TAMOXIFEN; TEMOZOLOMIDE; TOSITUMOMAB I 131; TRASTUZUMAB; WART VIRUS VACCINE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RECURRENCE; CANCER REGISTRY; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CANCER STATISTICS; CANCER SURVIVAL; CANCER THERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIET THERAPY; DRUG APPROVAL; DRUG TARGETING; ECHOMAMMOGRAPHY; EXERCISE; FOLLICULAR LYMPHOMA; GLIOBLASTOMA; HEAD AND NECK CANCER; HEALTH CARE PERSONNEL; HUMAN; KIDNEY CANCER; LIFESTYLE MODIFICATION; LOW FAT DIET; LUNG CANCER; MANTLE CELL LYMPHOMA; MEDICAL SOCIETY; MEDULLOBLASTOMA; PATIENT CARE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; UNITED STATES; VITAMIN SUPPLEMENTATION; WATCHFUL WAITING; ARTICLE; BLOOD DISEASE; BREAST TUMOR; FEMALE; FEMALE GENITAL TRACT TUMOR; GASTROINTESTINAL TUMOR; HEAD AND NECK TUMOR; LUNG TUMOR; MORTALITY; NEOPLASM; ONCOLOGY; RESEARCH; SKIN TUMOR; UROGENITAL TRACT TUMOR;

BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; GASTROINTESTINAL NEOPLASMS; GENITAL NEOPLASMS, FEMALE; HEAD AND NECK NEOPLASMS; HEMATOLOGIC NEOPLASMS; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; NEOPLASMS; RESEARCH; SKIN NEOPLASMS; UROGENITAL NEOPLASMS;

EID: 33644847618     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.8678     Document Type: Conference Paper

References (63)

1. List AF, Dewald G, Bennett J, et al: Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 study. J Clin Oncol 23, 2005 (abstr 5)
2. Barlogie B, Tricot G, Shaughnessy J, et al: Results of Total Therapy 2 (TT 2), a phase III randomized trial, to determine the role of thalidomide (THAL) in the upfront management of multiple myeloma (MM). J Clin Oncol 23, 2005 (suppl 16, abstr 6502)
3. Pfreundschuh MG, Ho A, Wolf M, et al: Treatment results of CHOP-21, CHOEP-21, MACOP-B and PMitCEBO with and without rituximab in young good-prognosis patients with aggressive lymphomas. J Clin Oncol 23:567s, 2005 (abstr 6529)
4. Kaminski MS, Tuck M, Estes J, et al: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441-449, 2005
5. Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-675, 2005
6. O'Connor OA, Wright J, Moskowitz C, et al: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23:676-684, 2005
7. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
8. Piccart-Gebhart MJ, Proctor M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
9. Miller KD et al: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. J Clin Oncol
10. Chlebowski RT et al: Dietary fat reduction in postmenopausal women with primary breast cancer: Phase III Women's Intervention Nutrition Study (WINS). J Clin Oncol 23:3s, 2005 (abstr 10)
11. Holmes MD, Chen WY, Feskanich D, et al: Physical activity and survival after breast cancer diagnosis. JAMA 293:2479-2486, 2005
12. Thürlimann B, Keshaviah A, Mouridsen H, et al: BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. J Clin Oncol 23:6s, 2005 (abstr 511)
13. ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005
14. Pisano ED, Gatsonis C, Hendrick E, et al: Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 353:1773-1783, 2005
15. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
16. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
17. Rutkowski S, Bode U, Deinlein F, et al: Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352: 978-986, 2005
18. deGramont A, Boni C, Navarro M, et al: Oxaliplatin/ 5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. 23:246s, 2005 (abstr 3501)
19. Wolmark N, Wieand HS, Kuebler JP, et al: A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP protocol C-07. J Clin Oncol 23:246s, 2005 (abstr LBA3500)
20. Giantonio BJ, Catalano PJ, Meropol NJ, et al: High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Hollywood, FL, ASCO Gastrointestinal Cancer Symposium January 2005 (abstr 169a)
21. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy in operable gastric and lower oesophageal cancer: Final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). J Clin Oncol 23:308s, 2005 (abstr 4001)
22. Rockey DC, Paulson E, Niedzwiecki D, et al: Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: Prospective comparison. Lancet 365:305-311, 2005
23. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 351:2704-2714, 2004
24. Demetri GD, van Oosterom AT, Blackstein M, et al: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. J Clin Oncol 23:308s, 2005 (abstr 4000)
25. Moore MJ, Goldstein D, Ham J, et al: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 23:1s, 2005 (abstr 1)
26. Bill-Axelson A, Holmberg L, Ruutu M, et al:, Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977-1984, 2005
27. Rini B, Rixe O, Bukowski R, et al: AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol 23:380s, 2005 (abstr 4509)
28. Motzer RJ, Rini BI, Michaelson MD, et al: Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). J Clin Oncol 23:380s, 2005 (abstr 4508)
29. Escudier B, Szczylik C, Eisen T, et al: Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 23:380s, 2005 (abstr 4510)
30. Ratain MJ, Eisen T, Stadler WM, et al: Final findings from a Phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 23:388s, 2005 (abstr 4544)
31. Spigel DR, Hainsworth JD, Sosman JA, et al: Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial. J Clin Oncol 23:387s, 2005 (abstr 4540)
32. Small EJ, Schellhammer PF, Higano C, et al: Immunotherapy (APC8015) for androgen independent prostate cancer (AIPC): Final survival data from a phase 3 randomized placebo-controlled trial. Orlando, FL, ASCO Prostate Cancer Symposium, February 2005
33. Harper DM, Franco EL, Wheeler C, et al: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 364:1757-1765, 2004
34. Villa LL, Costa RL, Petta CA, et al: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271-278, 2005
35. Skjeldestad FE et al: Prophylactic quadrivalent human papillomavirus (HPV) (Types 6,11,16,18) LI virus like particle (VLD) vaccine (Gardasil) reduces cervical intraepithelial neoplasia (CIN) 2/3 risk. Presented at the Annual Meeting of the Infectious Diseases Society of America, October 2005 (abstr LB-8a)
36. Vermorken J, Bourhis J, Trigo J, et al: Cetuximab (Erbitux) in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies. J Clin Oncol 23:501s, 2005 (abstr 5505)
37. Bonner JA, Harari PM, Giralt J, et al: Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx. J Clin Oncol 23:508s, 2005 (abstr 5533)
38. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597, 2005
39. Douillard J, Rosell R, Delena M, et al: ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up: On behalf of the Adjuvant Navelbine International Trialist Association. J Clin Oncol 624s, 2005 (abstr 7013)
40. Strauss GM, Herndon J, Maddaus MS, et al: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 22:621s, 2004 (abstr 7019)
41. Sandler AB, Gray R, Brahmer J, et al: Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J Clin Oncol 23:2s, 2005 (abstr 4)
42. Oeffinger KC, Mertens AC, Sklar CA, et al: Prevalence and severity of chronic diseases in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J Clin Oncol 23: 3s, 2005 (abstr 9)
43. Strouse JJ, Fears TR, Tucker MA, et al: Pediatric melanoma: Risk factor and survival analysis of the Surveillance, Epidemiology and End Results database. J Clin Oncol 23:4735-4741, 2005
44. Christenson LJ, Borrowman TA, Vachon CM, et al: Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 294:681-690, 2005
45. Sudba J, Lee JJ, Lippman SM, et al: Non-steroidal anti-inflammatory drugs and the risk of oral cancer in current and former smokers. J Clin Oncol 23:107s, 2005 (abstr 1007)
46. Cook NR, Lee IM, Gaziano JM, et al: Low-dose aspirin in the primary prevention of cancer: The Women's Health Study - A randomized controlled trial. JAMA 294:47-55, 2005
47. Chan AT, Giovannucci EL, Meyerhardt JA, et al: Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294:914-923, 2005
48. Bairati I, Meyer F, Gelinas M, et al: A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 97:481-488, 2005
49. Lee IM, Cook NR, Gaziano JM, et al: Vitamin E in the primary prevention of cardiovascular disease and cancer: The Women's Health Study: A randomized controlled trial. JAMA 294:56-65, 2005
50. Lonn E, Bosch J, Yusuf S, et al: Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. JAMA 293:1338-1347, 2005
51. Bjelakovic G, Nikolova D, Simonetti RG, et al: Antioxidant supplements for prevention of gastrointestinal cancers: A systematic review and meta-analysis. Lancet 364:1219-1228, 2004
52. Kochhar R, Khurana V, Bejjanki H, et al: Statins reduce breast cancer risk: A case control study in US female veterans. J Clin Oncol 23:7s, 2005 (abstr 514)
53. Khurana V, Kochhar R, Bejjanki HR, et al: Statins reduce the incidence of lung cancer: A study of half a million US veterans. J Clin Oncol 23:107s, 2005 (abstr 1006)
54. Singal R, Khurana V, Caldito G, et al: Statins and prostate cancer risk: A large case control study in veterans. J Clin Oncol 23:107s, 2005 (abstr 1004)
55. Poynter JN, Gruber SB, Higgins PD, et al: Statins and the risk of colorectal cancer. N Engl J Med 352:2184-2192, 2005
56. Bradley CJ, Gardiner J, Given CW, et al: Cancer, Medicaid enrollment, and survival disparities. Cancer 103:1712-1718, 2005
57. National Initiative on Cancer Care Quality: Next Steps. Chair: Catherine Khan. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005
58. Keating NL, Landrum MB, Meara E, et al: Do Increases in the market share of managed care influence quality of cancer care in the fee-for-service sector? J Natl Cancer Inst 97:257-264, 2005
59. Coburn NG, Swallow C, Quan ML, et al: Significant regional variation in treatment and survival of gastric cancer. J Clin Oncol 23:309s, 2005 (abstr 4004)
60. Hewitt M, Greenfield S, Stovall S From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC, Committee on Cancer Survivorship, Improving Care and Quality of Life, Institute of Medicine and National Research Council, 2005
61. Fuchs C, Meyerhardt JA, Heseltine DL, et al: Influence of regular aspirin use on survival for patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. J Clin Oncol 23:253s, 2005 (abstr 3530)
62. Meyerhardt JA, Heseltine D, Niedzwiecki D, et al: The impact of physical activity on patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. J Clin Oncol 23:254s, 2005 (abstr 3534)
63. Ahles TA, Saykin AJ, Furstenberg CT, et al: Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. J Clin Oncol 23:4399-4405, 2005